Stock A002800 SINSIN PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sinsin Pharmaceutical Co., Ltd

Equities

A002800

KR7002800001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 26/05/2024 BST 		5-day change 1st Jan Change
5,390 KRW 0.00% Intraday chart for Sinsin Pharmaceutical Co., Ltd -5.27% -13.62%
2023 Sinsin Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2017 Sinsin Pharm. Co., Ltd. has completed an IPO in the amount of KRW 14.625 billion. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 111,200 103,463 138,658 97,850 84,651 94,664
Enterprise Value (EV) 1 137,612 155,913 181,331 143,286 125,893 138,822
P/E ratio 38.4 x 48.4 x 382 x -66.3 x 19.2 x 20.2 x
Yield 0.45% 0.41% - - 0.9% 0.96%
Capitalization / Revenue 1.75 x 1.52 x 2.07 x 1.32 x 0.92 x 0.92 x
EV / Revenue 2.16 x 2.3 x 2.7 x 1.94 x 1.37 x 1.35 x
EV / EBITDA 32.9 x 44.5 x -114 x 61.5 x 13.7 x 14 x
EV / FCF -5.63 x -6.6 x -38.6 x -54.2 x 37.4 x -44 x
FCF Yield -17.7% -15.2% -2.59% -1.84% 2.67% -2.27%
Price to Book 2.04 x 1.84 x 2.47 x 1.78 x 1.42 x 1.52 x
Nbr of stocks (in thousands) 15,171 15,171 15,171 15,171 15,171 15,171
Reference price 2 7,330 6,820 9,140 6,450 5,580 6,240
Announcement Date 14/03/19 19/03/20 17/03/21 15/03/22 15/03/23 13/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 63,720 67,855 67,129 74,008 91,926 102,586
EBITDA 1 4,176 3,500 -1,586 2,329 9,184 9,941
EBIT 1 3,036 2,329 -4,170 -1,343 5,426 6,004
Operating Margin 4.76% 3.43% -6.21% -1.81% 5.9% 5.85%
Earnings before Tax (EBT) 1 3,362 2,131 -269.3 -1,747 4,047 3,995
Net income 1 2,896 2,138 362.7 -1,476 4,415 4,680
Net margin 4.54% 3.15% 0.54% -1.99% 4.8% 4.56%
EPS 2 190.9 140.9 23.91 -97.29 291.0 308.5
Free Cash Flow 1 -24,426 -23,625 -4,699 -2,642 3,362 -3,157
FCF margin -38.33% -34.82% -7% -3.57% 3.66% -3.08%
FCF Conversion (EBITDA) - - - - 36.61% -
FCF Conversion (Net income) - - - - 76.16% -
Dividend per Share 2 33.00 28.00 - - 50.00 60.00
Announcement Date 14/03/19 19/03/20 17/03/21 15/03/22 15/03/23 13/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 26,412 52,450 42,673 45,437 41,241 44,158
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 6.324 x 14.99 x -26.91 x 19.51 x 4.491 x 4.442 x
Free Cash Flow 1 -24,426 -23,625 -4,699 -2,642 3,362 -3,157
ROE (net income / shareholders' equity) 5.25% 3.65% 0.36% -2.62% 7.62% 7.64%
ROA (Net income/ Total Assets) 2.03% 1.23% -2.11% -0.72% 2.88% 3.06%
Assets 1 142,524 174,138 -17,213 204,449 153,288 153,169
Book Value Per Share 2 3,595 3,715 3,704 3,621 3,935 4,106
Cash Flow per Share 2 125.0 74.50 165.0 52.70 148.0 22.80
Capex 1 25,438 20,505 11,969 2,682 907 5,011
Capex / Sales 39.92% 30.22% 17.83% 3.62% 0.99% 4.88%
Announcement Date 14/03/19 19/03/20 17/03/21 15/03/22 15/03/23 13/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SINSIN PHARMACEUTICAL CO., LTD Stock Sinsin Pharmaceutical Co., Ltd
-13.62% 59.89M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.74% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.44% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.97% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A002800 Stock
  4. Financials Sinsin Pharmaceutical Co., Ltd